AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine
AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3 LUNA study, which evaluated atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, for the preventive treatment of menstrual migraine in adults.1 These results reinforce AbbVie's scientific expertise in migraine and its focus on advancing solutions for people living with complex and disabling migraine attacks.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.